74.47
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Low
61.66
High
137.61
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Emergent Biosolutions Inc | EBS | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 74.47 | 05:45:13 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 74.47 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 74.47 | USD |
Emergent Biosolutions Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 3.95B | 53.00M | 37.99M | $ 1.11B | $ 136.14M | 1.03 | 34.40 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Emergent Biosolutions News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EBS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 77.47 | 78.00 | 71.55 | 74.71 | 1,016,292 | -3.00 | -3.87% |
| 1 Month | 88.84 | 96.025 | 71.55 | 81.50 | 941,208 | -14.37 | -16.18% |
| 3 Months | 108.85 | 127.20 | 71.55 | 93.65 | 723,042 | -34.38 | -31.58% |
| 6 Months | 100.00 | 127.20 | 71.55 | 92.87 | 628,844 | -25.53 | -25.53% |
| 1 Year | 62.02 | 137.61 | 61.66 | 94.24 | 703,413 | 12.45 | 20.07% |
| 3 Years | 53.76 | 137.61 | 39.11 | 74.17 | 481,409 | 20.71 | 38.52% |
| 5 Years | 39.60 | 137.61 | 24.47 | 61.03 | 438,560 | 34.87 | 88.06% |
Emergent Biosolutions Description
| Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products. |
